XT
ELVN icon

XTX Topco’s Enliven Therapeutics ELVN Stock Holding History

XTX Topco’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Sell
38,323
-22,379
-37% -$620K 0.03% 1080
2025
Q4 		$935K Buy
60,702
+50,101
+473% +$998K 0.02% 1070
2025
Q3 		$0 Sell
10,601
-761
-7% -$15.3K ﹤0.01% 2736
2025
Q2 		$228K Sell
11,362
-10,487
-48% -$199K 0.01% 1620
2025
Q1 		$430K Buy
+21,849
New +$470K 0.02% 1134

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

XTX Topco's ELVN Position: Q1 2026 in Review

XTX Topco reduced its Enliven Therapeutics (ELVN) stake by 37% in Q1 2026, selling an estimated $620K and leaving 38,323 shares worth $1.5M. The position accounts for 0.03% of the portfolio, ranked #1080.

XTX Topco first reported a position in ELVN in Q1 2025 and has held it in 5 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • XTX Topco held 38,323 shares of Enliven Therapeutics worth $1.5M as of Q1 2026.
  • XTX Topco sold 22,379 Enliven Therapeutics shares in Q1 2026, an estimated $620K.
  • Enliven Therapeutics made up 0.03% of XTX Topco's portfolio in Q1 2026, its #1080 holding.
  • XTX Topco first reported a position in Enliven Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.